Author Archives: admin


Stem Cell Clinic > Articles by: admin

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

By Global News Feed

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights.

More here:
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

By Global News Feed

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2024, and provided a general business update.

Link:
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

By Global News Feed

Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024

See the rest here:
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

By Global News Feed

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request that Lykos Therapeutics complete a third confirmatory Phase 3 trial prior to allowing the approval of MDMA assisted therapy (MDMA-AT) for the treatment of Post Traumatic Stress Disorder.

See the original post:
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

eLabNext and US Lab Partners Enhance Digital Infrastructure for Life Science Companies

By Global News Feed

BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- eLabNext, an Eppendorf Group Company offering a flexible Digital Laboratory Platform equipped with a Laboratory Inventory Management System (LIMS) and Electronic Lab Notebook (ELN), announced today that they’ve entered into a “preferred vendor” partnership with US Lab Partners, a strategic consulting and advisory firm that provides life sciences companies with best-in-class labs, facilities, and EH&S programs.

Read the original post:
eLabNext and US Lab Partners Enhance Digital Infrastructure for Life Science Companies

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

By Global News Feed

REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 at 2:00 p.m. ET.

See more here:
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

→←